Esophageal cancer is a tumor that forms inside the esophagus. This tube starts in the back of the throat, goes through the ...

Each Initiative Has the Potential to Drive Significant Liquidity and Strengthen the Company’s Balance Sheet UNIONDALE, NY, Feb. 03, 2026 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (OTC: PRPH) (“ProPhase” ...

The San Antonio Fire Department is beyond proud but it has nothing to do with making a daring rescue or stopping a ...

Each Initiative Has the Potential to Drive Significant Liquidity and Strengthen the Company's Balance Sheet UNIONDALE, NY, Feb. 03, 2026 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (OTC: PRPH) ("ProPhase" ...

The Global Reflux Testing Products Market grows due to rising GERD cases and advancements in non-invasive diagnostics like wireless pH monitoring, overcoming compliance issues. Supported by AI, these ...

“Don’t get too excited,” President Marcos said as he dismissed rumors about his death as “highly exaggerated.” The rumors were sparked by what Malacañang described as “discomfort” that landed the ...

Johannes R. Kratz, MD, has been named as the inaugural chief of UCSF’s Division of Thoracic Surgery, one of the leading academic robotic thoracic surgery programs in the western U.S. He brings a track ...

Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $45.86, with a ...

Cryoablation for Barrett’s esophagus is something of a novelty, and the U.K. National Institute of Health and Care Excellence is considering an endorsement of the treatment.

New FDA-cleared version with tool detection and CE-marked version with additional quality (CAQ) features further strengthen MAGENTIQ-COLO™'s AI platform HAIFA, IL / ACCESS Newswire / January 26, ...

DelveInsight's Gastroesophageal Reflux Disease Market Insights report includes a comprehensive understanding of current treatment practices, gastroesophageal reflux disease emerging drugs, market ...

2025 total revenue expected to exceed $340 million, above the previously guided range of $327-335 million 2025 total test reports for our core revenue drivers (DecisionDx ®-Melanoma, TissueCypher ®) ...